Characteristics of patients with past HBV infection treated with ibrutinib (N = 21)
| Characteristic . | No. of patients . |
|---|---|
| Male sex | 15 (71) |
| Age, median (range), y | 66 (50-83) |
| Hematologic malignancy | |
| CLL | 15 (71) |
| Mantle cell lymphoma | 4 (19) |
| Waldenstrom macroglobulinemia | 2 (10) |
| Duration of ibrutinib (mo), median (range) | 9.5 (1-49) |
| Anti-CD20 therapy* in previous 2 y | 10 (48) |
| Allo-HCT | 5 (24) |
| Before ibrutinib | 2 (10) |
| After ibrutinib | 3 (14) |
| Baseline HBV surface antibody >10 IU/L† | 17 (89) |
| Quantitative HBsAb, median (range),† IU/L | 260 (<5, >1000) |
| HBV prophylaxis‡ | 1 (5) |
| Characteristic . | No. of patients . |
|---|---|
| Male sex | 15 (71) |
| Age, median (range), y | 66 (50-83) |
| Hematologic malignancy | |
| CLL | 15 (71) |
| Mantle cell lymphoma | 4 (19) |
| Waldenstrom macroglobulinemia | 2 (10) |
| Duration of ibrutinib (mo), median (range) | 9.5 (1-49) |
| Anti-CD20 therapy* in previous 2 y | 10 (48) |
| Allo-HCT | 5 (24) |
| Before ibrutinib | 2 (10) |
| After ibrutinib | 3 (14) |
| Baseline HBV surface antibody >10 IU/L† | 17 (89) |
| Quantitative HBsAb, median (range),† IU/L | 260 (<5, >1000) |
| HBV prophylaxis‡ | 1 (5) |
Data are presented as n (%) of patients unless indicated otherwise.
Anti-CD20 therapy given within 2 years before ibrutinib started included rituximab, ofatumumab, or obinutuzumab.
Includes information from 19 patients; baseline surface antibody before ibrutinib was not checked in 2 of 21 patients.
One patient was on HBV prophylaxis with entecavir that was started during a course of rituximab <1 year before ibrutinib was started. Entecavir continued during the entire ibrutinib course for this patient.